Clinical Study
Impact of Inappropriate Empiric Antimicrobial Therapy on Mortality of Septic Patients with Bacteremia: A Retrospective Study
Table 4
Type of first-dose empiric antimicrobials for sepsis by appropriateness of empiric antimicrobial therapy.
| | Type of antimicrobials (first dose) | All patients
() | Inappropriate first dose of antimicrobial therapy
() | Appropriate first dose of antimicrobial therapy
() |
| | Mono- or combination therapy | | | | | Monotherapy | 145 (63.3) | 45 (66.2) | 100 (62.1) | | Combination | 82 (35.8) | 21 (30.9) | 61 (37.9) | | 3rd generation cephalosporin | 100 (43.7) | 29 (42.6) | 71 (44.1) | | 4th generation cephalosporin | 32 (14.0) | 9 (13.2) | 23 (14.3) | | Carbapenems | 53 (23.1) | 17 (25.0) | 36 (22.4) | | (i) Imipenem | 26 (11.4) | 7 (10.3) | 19 (11.8) | | (ii) Meropenem | 24 (10.5) | 10 (14.7) | 14 (8.7) | | (iii) Doripenem | 1 (0.4) | 0 | 1 (0.6) | | Beta-lactam/beta-lactamase inhibitor* | 28 (12.2) | 6 (8.8) | 22 (13.7) | | Vancomycin | 26 (11.4) | 10 (14.7) | 16 (9.9) | | Aminoglycosides | 17 (7.4) | 5 (7.4) | 12 (7.5) | | Fluoroquinolones | 19 (8.3) | 7 (10.3) | 12 (7.5) | | (i) Ciprofloxacin | 13 (5.7) | 4 (5.9) | 9 (5.6) | | (ii) Levofloxacin | 6 (2.6) | 3 (4.4) | 3 (1.9) | | Colistin*** | 11 (4.8) | 0 | 11 (6.8) |
|
|
Piperacillin/tazobactam.
Amikacin.
.
|
